Neogenix Oncology to Present Data on Its Novel Antibody, NEO-201 at AACR's 2011 Annual Symposium

ROCKVILLE, Md.--(BUSINESS WIRE)--Apr 1, 2011 - Neogenix Oncology, Inc. announced today that members of its scientific staff will present laboratory studies of NEO-201, a novel monoclonal antibody in development to diagnose and treat solid tumors of the gastrointestinal tract, lung and respiratory tract, breast, and ovarian cancers. The presentation is scheduled at the American Association of Cancer Research (AACR) 102nd Annual Meeting being held April 1-6, 2011, at the Orange County Convention Center, Orlando, FL, USA.

NEO-201 (formerly 16C3) is a humanized monoclonal antibody being developed as a novel biological therapeutic agent for cancer, as well as a diagnostic test with high sensitivity and specificity. NEO-201 is in the Neogenix pipeline of antibodies intended to specifically target cancer tissues with little cross-reactivity to normal human tissues. The NEO-201 target appears to be a variant of CEACAM molecules that are expressed specifically by human colon, pancreatic, stomach, lung, esophagus, larynx, breast, and ovarian tumor tissues that in testing to date, have only occasionally shown minimal and weak cross-reactivity to normal tissues. The preclinical data to be presented includes tissue distribution, cell-specific mechanism of action, target description, in vivo anti-tumor efficacy and bio-distribution studies.

“We are excited to continue building our product pipeline. NEO-201 represents the next antibody in development that is moving towards an investigational new drug application. This preclinical data demonstrates the remarkable specificity of NEO-201 for a number of solid tumor types,” said Neogenix Chief Executive Officer, Philip M. Arlen, MD.

Poster Presentation Information:

Abstract Title: Characterization of a new antibody that reacts with a tumor-specific variant of CEACAM-5 and CEACAM-6

Poster Session Date/Time: Immunology 6; Tuesday April 5th at 1:00pm-5:00pm.

Permanent Abstract ID: 4582

Location: Exhibit Hall A4-C; Poster Session 31; Poster #24

The full abstract can be accessed through the AACR website http://www.aacr.org/ or the Neogenix Oncology website, www.neogenix.com. The complete study presentation poster will also be available on the Neogenix website, following the presentation.

About Neogenix Oncology

Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, breast, and other cancers. The company's portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work at its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic test for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NEO-101 antibody in patients with metastatic pancreatic and colorectal cancer. NEO-201 and NEO-301 are in preclinical development towards IND submission.

Forward Looking Statements

Certain statements contained in this release, including statements relating to the potential benefits of the company's product candidates, are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the company's SEC reports, including the company's annual report on Form 10-K and quarterly reports on Form 10-Q. These risks and uncertainties include, but are not limited to, risks associated with the company's ability to successfully complete its product development efforts and obtain required regulatory approvals, obtain additional funding, develop commercially feasible products and services, successfully complete adequate and well-controlled clinical trials and generate revenues. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Contact: RMT PR Management
RoseMarie Terenzio, 212-414-1909
Cell: 917-913-7226
rterenzio@rmtpr.com

 

 

Posted: April 2011

View comments

Hide
(web5)